We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+23.97%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$71.6M
AUM Growth
-$14.6M
Cap. Flow
-$22.9M
Cap. Flow %
-31.94%
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.81M
2
CDTX
Cidara Therapeutics
CDTX
+$1.29M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$1.06M
4
AKRO
Akero Therapeutics
AKRO
+$898K
5
TERN
Terns Pharmaceuticals
TERN
+$432K

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$5.28M
2
ELVN icon
Enliven Therapeutics
ELVN
+$5.22M
3
TRML
Tourmaline Bio
TRML
+$2.32M
4
MRK icon
Merck
MRK
+$2.06M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$1.84B
$9.42M 13.15%
1,014,940
-204,784
-17% -$1.6M
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
$8.75M 12.21%
179,569
+53,861
+43% +$1.29M
WHWK
3
Whitehawk Therapeutics
WHWK
$196M
$6.38M 8.9%
3,410,402
– –
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$5.31M 7.42%
63,436
-3,700
-6% -$277K
TRML
5
DELISTED
Tourmaline Bio
TRML
$4.54M 6.33%
283,682
-143,200
-34% -$2.32M
ASND icon
6
Ascendis Pharma A/S
ASND
$16B
$3.9M 5.44%
22,576
-764
-3% -$124K
INSM icon
7
Insmed
INSM
$21.3B
$3.73M 5.21%
37,070
-69,004
-65% -$5.28M
ARGX icon
8
argenx
ARGX
$52B
$3.69M 5.16%
6,702
-321
-5% -$186K
PRAX icon
9
Praxis Precision Medicines
PRAX
$8.52B
$3.12M 4.35%
74,087
-13,054
-15% -$497K
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.8B
$2.79M 3.89%
26,283
+16,708
+174% +$1.81M
TRVI icon
11
Trevi Therapeutics
TRVI
$2.54B
$2.7M 3.77%
493,735
-292,226
-37% -$1.82M
OCS icon
12
Oculis Holding
OCS
$718M
$2.07M 2.89%
106,718
-18,282
-15% -$336K
RVMD icon
13
Revolution Medicines
RVMD
$38.8B
$2.05M 2.86%
55,693
-10,969
-16% -$421K
BBOT
14
BridgeBio Oncology
BBOT
$661M
$1.99M 2.78%
187,257
– –
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
$1.73M 2.42%
463,864
+138,314
+42% +$432K
SRZN icon
16
Surrozen
SRZN
$253M
$1.52M 2.12%
170,000
– –
DRUG
17
Bright Minds Biosciences
DRUG
$724M
$1.27M 1.77%
48,474
-11,274
-19% -$338K
TSHA icon
18
Taysha Gene Therapies
TSHA
$1.66B
$1.12M 1.57%
+485,669
New +$1.06M
AKRO
19
DELISTED
Akero Therapeutics
AKRO
$1.06M 1.47%
+19,772
New +$898K
ZYME icon
20
Zymeworks
ZYME
$1.6B
$1.05M 1.47%
83,655
+15,196
+22% +$181K
LQDA icon
21
Liquidia Corp
LQDA
$7.46B
$945K 1.32%
75,876
-77,606
-51% -$1.15M
RARE icon
22
Ultragenyx Pharmaceutical
RARE
$2.46B
$866K 1.21%
23,814
+2,524
+12% +$91K
VSTM icon
23
Verastem
VSTM
$500M
$624K 0.87%
150,414
-25,586
-15% -$160K
FULC icon
24
Fulcrum Therapeutics
FULC
$283M
$410K 0.57%
+59,650
New +$319K
UNCY icon
25
Unicycive Therapeutics
UNCY
$138M
$300K 0.42%
62,899
-172,390
-73% -$1.07M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Acuta Capital Partners held 37 positions worth $71.6M, down 17% from $86.2M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Acuta Capital Partners withdrew a net $22.9M in Q2 2025, closing 9 positions and reducing 14 holdings. Its most notable exit was Enliven Therapeutics, an estimated $5.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Taysha Gene Therapies worth $1.12M.

  • Acuta Capital Partners's largest Q2 2025 buy was Taysha Gene Therapies: 485,669 shares worth $1.12M.
  • Acuta Capital Partners added most to Jazz Pharmaceuticals in Q2 2025, an estimated $1.81M increase.
  • Acuta Capital Partners's biggest Q2 2025 reduction was Insmed, cutting an estimated $5.28M.
  • Acuta Capital Partners fully exited Enliven Therapeutics in Q2 2025, selling an estimated $5.22M.
  • Acuta Capital Partners's ten largest holdings make up 72% of its $71.6M portfolio in Q2 2025.
  • Acuta Capital Partners opened 3 new positions and closed 9 in Q2 2025.
  • Acuta Capital Partners's portfolio value fell 17% quarter-over-quarter to $71.6M.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.